CommentaryParenchymal pressure injury Ca2+ entry mechanism in pancreatitis
Section snippets
Declaration of Competing Interest
RS has received research support and/or funding from Calcimedica, Cypralis, GlaxoSmithKline, MSD/Merck and Novartis, has been a consultant for AbbVie, Calcimedica, Cypralis, Eagle Pharmaceuticals, Novartis and Takeda (all funds to the University of Liverpool), and is collaborating in the IMI2 TransBioLine project with multiple public and private institutions including Janssen, Lilly, MSD/Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.
Acknowledgements
RS is funded by the U.K. Medical Research Council and National Institute for Health Research, European Union Innovative Medicines Initiative, GlaxoSmithKline PLC and Hampson Trust, and is an NIHR Senior Investigator.
References (10)
- et al.
Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum
Gastroenterology
(1993) - et al.
Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity
Cell Metab
(2017) - et al.
Management of severe acute pancreatitis
BMJ
(2019) - et al.
TRPV4 channel opening mediates pressure-induced pancreatitis initiated by Piezo1 activation
J Clin Invest
(2020 Jan) - et al.
Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models
Gastroenterology
(2015)
There are more references available in the full text version of this article.
Cited by (4)
Acute pancreatitis: Pathogenesis and emerging therapies
2024, Journal of PancreatologyAcute Pancreatitis: Diagnosis and Treatment
2022, Drugs
© 2020 Elsevier Ltd. All rights reserved.